Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2009 1
2012 3
2014 1
2015 1
2016 1
2017 1
2018 2
2019 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma.
Wan M, Zhang W, Huang H, Fang X, Chen Y, Tian Y, Yao Y, Weng H, Chen Z, Yu L, Tian Y, Huang H, Li X, Hong H, Lin T. Wan M, et al. Clin Exp Med. 2024 Mar 30;24(1):64. doi: 10.1007/s10238-024-01326-y. Clin Exp Med. 2024. PMID: 38554186 Free PMC article.
The aim of this study is to identify prognostic indicators that affect survival and response and establish the first survival prediction nomogram for advanced DLBCL. A total of 402 patients with advanced DLBCL were enrolled in this study. COX multivariate analysis w …
The aim of this study is to identify prognostic indicators that affect survival and response and establish the first survival pred …
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD. Sharman JP, et al. Leuk Lymphoma. 2019 Apr;60(4):894-903. doi: 10.1080/10428194.2018.1515940. Epub 2018 Oct 2. Leuk Lymphoma. 2019. PMID: 30277102 Free PMC article. Clinical Trial.
Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
Takahashi H, Miura K, Nakagawa M, Sugitani M, Amano Y, Kurita D, Sakagami M, Ohtake S, Uchino Y, Kodaira H, Iriyama N, Kobayashi S, Hojo A, Kobayashi Y, Hirabayashi Y, Kusuda M, Hatta Y, Nakayama T, Takei M. Takahashi H, et al. Leuk Lymphoma. 2016 Dec;57(12):2784-2790. doi: 10.3109/10428194.2016.1167205. Epub 2016 Apr 13. Leuk Lymphoma. 2016. PMID: 27071312
Co-expression of MYC and BCL2 proteins in diffuse large B-cell lymphoma (DLBCL), or 'double-expressor lymphoma' (DEL), results in poor patient prognosis, but the significance of DEL when aggressive treatments are applied remains uncertain. We performed a retrospective anal …
Co-expression of MYC and BCL2 proteins in diffuse large B-cell lymphoma (DLBCL), or 'double-expressor lymphoma' (DEL), results in poor patie …
Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma.
Milanovic N, Matkovic S, Ristic D, Jelic S, Petrovic M. Milanovic N, et al. J BUON. 2012 Jul-Sep;17(3):497-501. J BUON. 2012. PMID: 23033288
PURPOSE: Lactate dehydrogenase (LDH) and beta-2 microglobulin (B2M) are incorporated in the so-called "serologic staging system", as independent parameters for predicting time to treatment failure (TTF) and overall survival (OS) for aggressive non-Hodgkin's lymphoma (NHL) …
PURPOSE: Lactate dehydrogenase (LDH) and beta-2 microglobulin (B2M) are incorporated in the so-called "serologic staging system", as indepen …
Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study.
Fluge Ø, Mannsåker B, Torp A, Mjaaland I, Helgeland L, Klos J, Mella O, Berentsen S, Meyer P. Fluge Ø, et al. Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):125-135.e3. doi: 10.1016/j.clml.2017.12.002. Epub 2017 Dec 24. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29352718 Free article.
RESULTS: There were no differences between hospitals in patient characteristics, use of rituximab, number of chemotherapy courses or cumulative doses, or in distribution of response categories after chemotherapy. The use of RT was significantly different: 17 patients (23%) …
RESULTS: There were no differences between hospitals in patient characteristics, use of rituximab, number of chemotherapy courses or …
Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma.
Yamauchi T, Matsuda Y, Takai M, Tasaki T, Tai K, Hosono N, Negoro E, Ikegaya S, Takagi K, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T. Yamauchi T, et al. Anticancer Res. 2012 Nov;32(11):5051-7. Anticancer Res. 2012. PMID: 23155278
Thus, the present study suggests sIL2R levels to be a valuable predictor for the prognosis of patients with advanced DLBCL....
Thus, the present study suggests sIL2R levels to be a valuable predictor for the prognosis of patients with advanced DLBCL....
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. Stopeck AT, et al. Blood. 2012 Aug 9;120(6):1210-7. doi: 10.1182/blood-2012-04-423079. Epub 2012 Jun 25. Blood. 2012. PMID: 22734071 Free PMC article. Clinical Trial.
For the 64 eligible patients, median age was 68 years, and 60% had International Prognostic Index scores more than or equal to 3. The observed 1- and 2-year PFS estimates were 77% and 69%, respectively. ...
For the 64 eligible patients, median age was 68 years, and 60% had International Prognostic Index scores more than or equal to 3. The …
Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D, Miura K, Nakagawa M, Ohtake S, Sakagami M, Uchino Y, Takahashi H, Kiso S, Hojo A, Kodaira H, Yagi M, Hirabayashi Y, Kobayashi Y, Iriyama N, Kobayashi S, Hatta Y, Kura Y, Sugitani M, Takei M. Kurita D, et al. Int J Hematol. 2015 Jun;101(6):585-93. doi: 10.1007/s12185-015-1780-6. Epub 2015 Mar 17. Int J Hematol. 2015. PMID: 25776837
This treatment was given to 51 de novo DLBCL patients with a median age of 54 (range 19-65), who were categorized as high/high-intermediate risk by the age-adjusted International Prognostic Index. Treatment was given every 3 weeks up to three courses. ...
This treatment was given to 51 de novo DLBCL patients with a median age of 54 (range 19-65), who were categorized as high/high-intermediate …
11 results